Business
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations.
About this update from Medite Cancer Diagnostics Inc
[{"type":"text","content":"\n \n \n MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations\n \n \nMEDITE Cancer Diagnostics Announces Reorganization of Germany Operations\n \n ORLANDO, FL--(Marketwired - May 10, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the \"Company\") specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces further restructuring of its organization in Germany to position the Company for revenue growth and profitability.\n On May 4, 2017, the Board of Directors (the \"Board\") of MEDITE Cancer Diagnostics, Inc. (the \"Company\") accepted the resignation of Michaela Ott as Chief Operating Officer of the Company, effective immediately. Ms. Ott shall remain on the Board of Directors of the Company. Further, the Board accepted Ms. Ott's resignation from her position as Managing Director of the Company's wholly-owned subsidiary, Medite GmbH, as well as managing director of CytoGlobe GmbH, Burgdorf, a wholly owned subsidiary of Medite GmbH, effective immediately. Ms. Ott shall further resign from her position as Managing Director of Medite GmbH, Austria, also a wholly-owned subsidiary of Medite GmbH, effective no later than September 30, 2017.\n Further, on May 4, 2017, the Board also accepted the resignation of Michael Ott as Chairman of the Board, effective immediately. Mr. Ott shall remain on the Board of Directors of the Company. Mr. Ott further resigned as Managing Director of the Company's wholly-owned German subsidiary, Medite GmbH, as well as from his position as Managing Director of CytoGlobe GmbH, Burgdorf, a wholly-owned subsidiary of Medite GmbH, effective immediately. Mr. Ott shall resign from his position as Managing Director of Medite sp. z. o.o., Poland, also a wholly-owned subsidiary of Medite GmbH, effective no later than September 30, 2017.\n On May 4, 2017, the Board thereafter, by unanimous consent, appointed Stephen Von Rump to the position of Chief Commercialization and Strategy Officer of the Company to serve until such time as his removal or resignation. Mr. Von Rump was further appointed to the position of Managing Director of Medite GmbH, until such time as his resignation or termination.\n On May 4, 2017, the Board unanimously elected Dav...